Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223013 | 0.79 | DGAT1 (0.42) | TDP1ELANEHDAC6DGAT1HDAC1 | |
| SCHEMBL4494018 | 0.75 | TDP1 (0.39) | TDP1ELANECTSKHDAC6DGAT1 | |
| SCHEMBL22129786 | 0.74 | ELANE (0.39) | TDP1ELANEHDAC6DGAT1HDAC1 | |
| SCHEMBL29121 | 0.73 | DGAT1 (0.46) | TDP1ELANEHDAC6DGAT1HDAC1 | |
| SCHEMBL17727759 | 0.72 | HDAC6 (0.38) | ELANEHDAC6DGAT1HDAC1HDAC2 | |
| SCHEMBL1333110 | 0.72 | TSHR (0.40) | TDP1ELANEHDAC6DGAT1HDAC1 | |
| SCHEMBL538708 | 0.70 | ELANE (0.36) | TDP1ELANEHDAC6DGAT1HDAC1 | |
| Hydrogen Peroxide SCHEMBL26665096 | 0.70 | ELANE (0.36) | TDP1ELANEHDAC6DGAT1HDAC1 | |
| Ammonia Solution, Strong SCHEMBL9998492 | 0.70 | DGAT1 (0.43) | TDP1ELANECTSKHDAC6DGAT1 | |
| Methyl Alcohol SCHEMBL28820308 | 0.70 | DGAT1 (0.43) | TDP1ELANECTSKHDAC6DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-08-24 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | TDP1 1431/4885ELANE 1309/4885CTSK 3204/4885 |
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | GTF3C4, BRD4, CUL4B | TDP1 3373/4885ELANE 2894/4885CTSK 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.